Inventor · disambiguated record
Guy Georges
Also filed as: GEORGES GUY
71 granted patents·59 pending applications·511 citations·filing 2001–2025
99Inventor score
Top patents by PatentIndex Score
130 records- 0197US10323089B2Anti-transferrin receptor antibodies with tailored affinityHOFFMANN LA ROCHE·Filed 2017·Granted Jun 18, 2019·25 cites·9 claims
- 0297US8268314B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2009·Granted Sep 18, 2012·70 cites·18 claims
- 0395US11584793B2Anti-transferrin receptor antibodies with tailored affinityHOFFMANN LA ROCHE·Filed 2019·Granted Feb 21, 2023·8 cites·20 claims
- 0495US11286300B2Humanized anti-human CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 29, 2022·11 cites·8 claims
- 0595US7462639B2Aminopyrazole derivativesHOFFMANN LA ROCHE·Filed 2006·Granted Dec 9, 2008·46 cites·17 claims
- 0694US12252533B2Anti-transferrin receptor antibodies with tailored affinityHOFFMANN LA ROCHE·Filed 2022·Granted Mar 18, 2025·1 cites·11 claims
- 0794US8703130B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2012·Granted Apr 22, 2014·23 cites·12 claims
- 0893US8003099B2Antibodies against human IL17 and uses thereofROCHE PALO ALTO LLC·Filed 2009·Granted Aug 23, 2011·44 cites·17 claims
- 0992US11608376B2Tumor-targeted agonistic CD28 antigen binding moleculesHOFFMANN LA ROCHE·Filed 2019·Granted Mar 21, 2023·14 cites·49 claims
- 1092US9708396B2Bispecific anti-VEGF/anti-ANG-2 antibodiesHOFFMANN LA ROCHE·Filed 2014·Granted Jul 18, 2017·16 cites·17 claims
- 1191US10822402B2Humanized anti-tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2017·Granted Nov 3, 2020·4 cites·12 claims
- 1291US10501521B2Disulfide-linked multivalent MHC class I comprising multi-function proteinsHOFFMANN LA ROCHE·Filed 2013·Granted Dec 10, 2019·39 cites·9 claims
- 1391US10072087B2Antibodies against human CSF-1R and uses thereofHOFFMANN LA ROCHE·Filed 2017·Granted Sep 11, 2018·5 cites·20 claims
- 1491US9388222B2Modified Pseudomonas exotoxin AUS HEALTH·Filed 2014·Granted Jul 12, 2016·15 cites·42 claims
- 1591US7572809B2Isoquinoline aminopyrazole derivativesHOFFMANN LA ROCHE·Filed 2006·Granted Aug 11, 2009·11 cites·74 claims
- 1690US11214622B2Antibodies specific for DR5 and methods of useROCHE GLYCART AG·Filed 2018·Granted Jan 4, 2022·6 cites·13 claims
- 1790US9926379B2Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5ROCHE GLYCART AG·Filed 2014·Granted Mar 27, 2018·17 cites·28 claims
- 1889US10806795B2Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttlesHOFFMANN LA ROCHE·Filed 2019·Granted Oct 20, 2020·3 cites·17 claims
- 1989US6531472B2Tetralone derivativesHOFFMANN LA ROCHE·Filed 2001·Granted Mar 11, 2003·23 cites·8 claims
- 2088US10287358B2Antibodies against human CSF-1R and uses thereofHOFFMANN LA ROCHE·Filed 2018·Granted May 14, 2019·3 cites·20 claims
- 2187US9765153B2Anti-biotin antibodies and methods of useHOFFMANN LA ROCHE·Filed 2014·Granted Sep 19, 2017·7 cites·20 claims
- 2287US8907069B2Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agentBRINKMANN ULRICH·Filed 2010·Granted Dec 9, 2014·7 cites·17 claims
- 2386US9309319B2Antibodies against human IL33R and uses thereofHOFFMANN LA ROCHE·Filed 2014·Granted Apr 12, 2016·8 cites·7 claims
- 2485US11273223B2Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttlesHOFFMANN LA ROCHE·Filed 2020·Granted Mar 15, 2022·1 cites·28 claims
- 2585US9862763B2Humanized anti-tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Jan 9, 2018·4 cites·13 claims
- 2685US9346886B2Humanized anti-CDCP1 antibodiesROCHE GLYCART AG·Filed 2012·Granted May 24, 2016·8 cites·2 claims
- 2784US12297263B2Humanized anti-Tau(PS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted May 13, 2025·0 cites·6 claims
- 2884US11827711B2Antibodies binding to NKG2DHOFFMANN LA ROCHE·Filed 2020·Granted Nov 28, 2023·1 cites·27 claims
- 2984US2023399391A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3084US2024270844A1Anti-tim3 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 3183US10730938B2Bispecific antibodies and methods of use in ophthalmologyHOFFMANN LA ROCHE·Filed 2017·Granted Aug 4, 2020·3 cites·13 claims
- 3283US10344085B2Anti-IL-1beta antibodiesHOFFMANN LA ROCHE·Filed 2017·Granted Jul 9, 2019·5 cites·9 claims
- 3383US2024294642A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3482US11739142B2Bispecific anti-CCL2 antibodiesHOFFMANN LA ROCHE·Filed 2020·Granted Aug 29, 2023·1 cites·2 claims
- 3582US10561737B2Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttlesHOFFMANN LA ROCHE·Filed 2014·Granted Feb 18, 2020·4 cites·17 claims
- 3682US9725512B2HER3 antibodies binding to the beta-hairpin of HER3HOFFMANN LA ROCHE·Filed 2013·Granted Aug 8, 2017·5 cites·8 claims
- 3782US9562091B2Humanized anti-Tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2014·Granted Feb 7, 2017·4 cites·10 claims
- 3882US9050375B2Bi-specific digoxigenin binding antibodiesBRAMLAGE BIRGIT·Filed 2010·Granted Jun 9, 2015·6 cites·17 claims
- 3982US7235574B2Pentafluorosulfanyl compoundsHOFFMANN LA ROCHE·Filed 2005·Granted Jun 26, 2007·6 cites·15 claims
- 4082US7226923B2Phthalazinone derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Jun 5, 2007·8 cites·49 claims
- 4182US2025376523A1Humanized anti-human cd19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 4281US7163953B2Benzylether derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Jan 16, 2007·4 cites·11 claims
- 4381US2023183349A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 4480US10465000B2Humanized anti-Tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Nov 5, 2019·2 cites·6 claims
- 4580US8394928B2Humanized anti-CDCP1 antibodiesAUER JOHANNES·Filed 2010·Granted Mar 12, 2013·7 cites·33 claims
- 4680US2023279109A1Anti-tim3 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 4778US10584178B2Bispecific HER2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 10, 2020·2 cites·6 claims
- 4878US10517945B2Covalently linked antigen-antibody conjugatesHOFFMANN LA ROCHE·Filed 2014·Granted Dec 31, 2019·3 cites·16 claims
- 4978US9925272B2Anti-theophylline antibodies and methods of useHOFFMANN LA ROCHE·Filed 2014·Granted Mar 27, 2018·3 cites·15 claims
- 5078US2025179205A1Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fapHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
Showing the top 50 of 130 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Guy Georges files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →